The problems continue to mount for Boston Scientific Corp. (NYSE:BSX) and its beleaguered Guidant Corp. cardiac rhythm management division. The $26 billion acquisition got off on the wrong foot soon after it closed in 2006, when the Natick, Mass.-based medical device maker was forced to recall tens of thousands of potentially defective Guidant pacemakers and […]
The price of Boston Scientific Corp.’s (NYSE:BSX) $26 billion acquisition of Guidant Corp. just got a little steeper, after the subsidiary’s guilty plea to charges that it deliberately concealing problems with its implantable defibrillators earning it a $296 million penalty — the largest criminal penalty ever imposed on a device maker for violating the Food, […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
For Boston Scientific Corp. to have any chance of reviving its ailing peripheral vascular business, it must rely on a 46-year-old executive who used to sell Budweiser and Bud Light for a living. Beer and stents may seem worlds apart, but Joe Fitzgerald says his time at Anheuser-Busch Cos. taught him how to nurture a […]
A federal judge denied Johnson & Johnson's bid to revive its $5.5 billion anti-competition and breach of contract lawsuit against Boston Scientific Corp. and Abbott over its abortive attempt to acquire Guidant Corp. in 2005.
St. Jude's purchase of Advanced Neuromodulation Systems In Texas has given the Minnesota medical device maker a much-needed boost in revenue at a time when global demand for mechanical heart devices starts to wane.
It's no secret that digesting Guidant proved long and taxing for Boston Scientific. Aside from near universal consensus that Boston Scientific wildly overpaid for Guidant in 2006, mostly to keep the company from falling into rival Johnson & Johnson's hands, Guidant's legal and regulatory woes hobbled its new owner.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Federal prosecutors have been probing whether Guidant paid illegal kickbacks to doctors to recommend devices through "post-market surveys."